Refine
Language
- English (25)
Has Fulltext
- yes (25)
Is part of the Bibliography
- no (25)
Keywords
- SARS-CoV-2 (9)
- COVID-19 (5)
- COVID-19 surveillance (2)
- Omicron (2)
- PCR (2)
- SARS-CoV-2 monitoring (2)
- corona virus (2)
- ALF (1)
- Ag-RDT (1)
- Antigen test (1)
- B.1.1.529 (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BA.4 (1)
- BA.5 (1)
- BNT162b2 (1)
- BNT2b2 (1)
- Bio safety (1)
- CPE (1)
- ChAdOx1-S (1)
- Corona virus (1)
- Detection workflow (1)
- Epsilon (1)
- HBV (1)
- Heterologous prime-boost (1)
- Immunogenicity (1)
- Inactivation (1)
- Kappa (1)
- N501Y (1)
- NGS (1)
- Omicron variant BA.1 (1)
- POCT (1)
- Quarantine (1)
- Reactogenicity (1)
- SARS-CoV-2 testing (1)
- Stability (1)
- Travel regulations (1)
- Variant of concern (1)
- Wastewater-based epidemiology (WBE) (1)
- acute liver failure (1)
- animal experiments (1)
- cell culture (1)
- coronavirus (1)
- delta (1)
- diagnostic test (1)
- drug screening (1)
- genetic diversity (1)
- hepatitis B (1)
- high throughput (1)
- infection model (1)
- infectivity (1)
- interferon induction (1)
- interferon sensitivity (1)
- intranasal administration (1)
- live cell imaging (1)
- mRNA1273 (1)
- mice (1)
- molecular surveillance (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- natural selection (1)
- neutralizing antibody (1)
- qRT-PCR detection (1)
- reactivation (1)
- spike mutation (1)
- test protocol (1)
- topical administration (1)
- transduction (1)
- vaccination (1)
- variant of concern (1)
- virus (1)
- wastewater-based epidemiology (WBE) (1)
Institute
- Medizin (25)
Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020
(2020)
Containment strategies and clinical management of coronavirus disease (COVID-19) patients during the current pandemic depend on reliable diagnostic PCR assays for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we compare 11 different RT-PCR test systems used in seven diagnostic laboratories in Germany in March 2020. While most assays performed well, we identified detection problems in a commonly used assay that may have resulted in false-negative test results during the first weeks of the pandemic.
The new variant of concern (VOC) of SARS-CoV-2, Omicron (B.1.1.529), is genetically very different from other VOCs. We compared Omicron with the preceding VOC Delta (B.1.617.2) and the wildtype (wt) strain (B.1) with respect to their interactions with the antiviral interferon (IFN-alpha/beta) response in infected cells. Our data indicate that IFN induction by Omicron is low and comparable to the wt, whereas Delta showed an increased IFN induction. However, Omicron exceeded both the wt and the Delta strain with respect to the ability to withstand the antiviral state imposed by IFN-alpha.
Vaccines are central to controlling the coronavirus disease 2019 (COVID-19) pandemic but the durability of protection is limited for currently approved COVID-19 vaccines. Further, the emergence of variants of concern (VoCs) that evade immune recognition has reduced vaccine effectiveness, compounding the problem. Here, we show that a single dose of a murine cytomegalovirus (MCMV)-based vaccine, which expresses the spike (S) protein of the virus circulating early in the pandemic (MCMVS), protects highly susceptible K18-hACE2 mice from clinical symptoms and death upon challenge with a lethal dose of D614G SARS-CoV-2. Moreover, MCMVS vaccination controlled two immune-evading VoCs, the Beta (B.1.135) and the Omicron (BA.1) variants in BALB/c mice, and S-specific immunity was maintained for at least 5 months after immunization, where neutralizing titers against all tested VoCs were higher at 5-months than at 1-month post-vaccination. Thus, cytomegalovirus (CMV)-based vector vaccines might allow for long-term protection against COVID-19.
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.
We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R.
We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.5-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab.
In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which however, might be circumvented by a combination therapy with casirivimab together.
The SARS-CoV-2 Omicron variant is currently causing a large number of infections in many countries. A number of antiviral agents are approved or in clinical testing for the treatment of COVID-19. Despite the high number of mutations in the Omicron variant, we here show that Omicron isolates display similar sensitivity to eight of the most important anti-SARS-CoV-2 drugs and drug candidates (including remdesivir, molnupiravir, and PF-07321332, the active compound in paxlovid), which is of timely relevance for the treatment of the increasing number of Omicron patients. Most importantly, we also found that the Omicron variant displays a reduced capability of antagonising the host cell interferon response. This provides a potential mechanistic explanation for the clinically observed reduced pathogenicity of Omicron variant viruses compared to Delta variant viruses.